Drug-Free & Non-Invasive
Real-Time Biofeedback Therapy
App-Controlled & Voice-Guided
Advancing Along FDA Certification Path
Recurring Revenue Model (Rental + Platform)
Invest in the Future of Drug-Free Pain Relief
Nexxt MedTech is pioneering a smarter, non-invasive solution to chronic pain-powered by adaptive biofeedback and 30+ years of clinical research.
Our Version 2.0 device is ready for mass-market rollout. We're raising $4M to fund commercialization and unlock scalable, recurring revenue.
Drug-Free & Non-Invasive
Real-Time Biofeedback Therapy
App-Controlled & Voice-Guided
Advancing Along FDA Certification Path
Recurring Revenue Model (Rental + Platform)
Drug-Free & Non-Invasive
Real-Time Biofeedback Therapy
App-Controlled & Voice-Guided
Advancing Along FDA Certification Path
Recurring Revenue Model (Rental + Platform)
Drug-Free & Non-Invasive
Real-Time Biofeedback Therapy
App-Controlled & Voice-Guided
Advancing Along FDA Certification Path
Recurring Revenue Model (Rental + Platform)
The Pain Crisis
Chronic pain is a silent epidemic affecting more than 51 million Americans and 17 million live with high-impact pain that limits their daily lives.
Addictive prescriptions
Invasive surgeries & clinical visits
Bulky or ineffective devices
1 in 4 opioid users began with a pain prescription. Nexxt MedTech is offering a better path-without dependency, pills, or procedures.
Personalized Relief. At Home. In Real Time.
Introducing Nexxt
NexxtMed's Version 2.0 uses Quantum BioPhysics Electrostimulation to adapt to the user's body-up to 300x per second. It's safe, smart, and scalable.
Chronic Pain
The Pain Crisis
Chronic pain affects 51 million Americans, costs the U.S. up to $635 billion a year, and often drives opioid addiction. Solving it means restoring lives, preventing dependency, and reducing a massive national burden.
Closed-loop biofeedback
Voice control for older users
No prescription required
Portable and user-friendly design
App-guided therapy sessions
Real Benefits
Unlike many traditional pain treatments, Nexxt MedTech’s system is designed with safety at its core. By combining advanced biofeedback with non-invasive therapy, it delivers effective relief without the risks that often come with drugs or invasive procedures. Here’s why it’s a safer choice:
Non-invasive, drug-free
Designed for seniors & chronic pain users
Supports independence, mobility, and peace of mind
Grounded in 30+ years of scientific research
Benefits For You
Why Now?
The chronic pain market is growing. So is the demand for at-home, non-opioid, and digital health solutions. Nexxt MedTech sits at the center of all three.
Version 2.0 is finalizing production
Primary demographic: older adults (65+)
Scaled rollout targeting high-need markets
FDA Class II certification in progress
Platform built for recurring revenue
Use of Funds
Funds will drive the final development, certification, and launch of Nexxt MedTech’s home-use pain relief device — targeting key milestones in engineering, approvals, marketing, and operations to speed market entry and position the company for rapid growth.
Our Offers
What Investors Get
Equity Ownership. Scalable Market Access. This is a structured MedTech opportunity—not theoretical. As an investor, you’ll receive:
Core Benefits
Early-Stage Equity
• Common shares at $20/share
• Minimum investment: $25K
• $4M raise to launch Version 2.0 nationally
Strong Projected Returns
• $17M EBITDA forecast by Year 3
• Scalable recurring revenue (rentals + subscriptions)
Priority Participation in Future Rounds
• First look at follow-on raises
• Potential for preferred access if equity expands
Quarterly Reporting & Financial Transparency
• Regular investor updates
• Access to team Q&A webinars and field progress reports
Planned SEC Reg A+ Submission
• Targeted Reg A public registration within 3 years
• Designed to promote growth
Opportunities
Market Opportunity
$200B+ in annual economic cost from chronic pain
51.6M+ Americans suffering
Addressable TAM includes aging U.S. population, veterans, and non-opioid seekers
Recurring revenue through hybrid model: rentals + app platform ($400/year)
Scalable into insurance, HSA/FSA, and clinical distribution later
How To Invest
Getting started is easy. Here’s how to become an early investor in NexxtMed
Complete a short form to verify accreditation and receive access to our investor materials. Accredited investors only.
Once verified, review the opportunity documents, ask questions, and commit funds securely. We provide full transparency and clear documentation to support your investment decision.
Once committed, your funds help launch Version 2.0 and scale our recurring revenue platform. You’ll receive quarterly updates and have priority access to follow-on rounds.
Frequently Asked
Questions
What is NexxtMed?
NexxtMed is a MedTech company developing a home-use device that delivers non-invasive, drug-free pain relief using adaptive biofeedback. It’s designed to help the 50M+ Americans suffering from chronic pain—especially older adults seeking alternatives to opioids and invasive procedures.
How much are you raising and why?
We are raising $4 million to finalize the design, certification, and go-to-market launch of our Version 2.0 device. Funds will support manufacturing, FDA Class II submission, and the rollout of our direct-to-consumer subscription model.
What do investors receive?
Investors receive common equity at $20/share with a minimum investment of $25,000. They also gain access to quarterly updates, early follow-on rounds, and a planned Reg A public offering (targeted in 3 years).
What are the key terms of the offering?
Offering Type:
• Reg D 506(c) (accredited investors only)
• Price per Share: $20
• Planned SEC Reg A+ filing or strategic M&A
• Projected EBITDA: $17M by Year 3
Who can invest?
Only verified accredited investors under SEC Rule 506(c) may participate. This includes individuals with a net worth over $1M (excluding their home) or annual income exceeding $200K ($300K if joint).
What makes NexxtMed different from other health startups?
NexxtMed combines::
• 30+ years of research in bioelectromedicine
• A drug-free, real-time pain relief platform
• Recurring revenue via rental + software
• Early market traction and a clear FDA path
It's mission-driven but engineered for commercial success and investor returns.
How do I get updates on my investment?
Investors receive quarterly email reports, updates on FDA milestones, and access to investor Q&A sessions. We’re committed to financial transparency and open communication.
Are there any legal or compliance notes?
Yes. This is a 506(c) offering available to accredited investors only. All forward-looking statements are projections and not guarantees. Full offering materials are shared after accreditation is verified.
Reg D 506 (C)
Investor Compliance (Reg D 506(c))
This is a 506(c) private offering available to accredited investors only. NexxtMed is at the intersection of
Feature Headline
Chronic pain treatment
Feature Headline
Consumer MedTech
Feature Headline
Digital health and wellness
Get More Info
Ready to Learn More?
We’re building more than a product - we’re changing how pain is treated, how patients find relief, and how investors generate returns from ethical innovation. Learn More
Ready to Learn More?
NexxtMed's Version 2.0 uses Quantum BioPhysics Electrostimulation to adapt to the user's body-up to 300x per second. It's safe, smart, and scalable.
Next MedTech HQ
427 Wright Street, Suite 205 Lakewood, CO 80228, USA
+1 (303) 834-2789
Legal Disclaimer
This landing page is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. Any offering will be made solely under Rule 506(c) of Regulation D to verified Accredited Investors. All forward-looking statements are estimates and not guarantees.